https://botanixpharma.com/wp-content/uploads/Botanix-Euroz-2.png 321 845 Haley Chartres /wp-content/uploads/botanix-logo.png Haley Chartres2022-03-01 20:59:002023-03-13 21:16:16Euroz Hartleys Report | 1 March 2022
Euroz Hartleys Report | 1 March 2022
Botanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly update.
Analyst Seth Lizee commented:
“The company is looking to shake up big markets in dermatology and antimicrobials with its four clinical programs. The prize, should individual programs ultimately be clinically successful, is huge.”